Rubin Lab

RECENT LAB PUBLICATIONS

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.

Rubin DT, Reinisch W, Greuter T, Kotze PG, Pinheiro M, Mundayat R, Maller E, Fellmann M, Lawendy N, Modesto I, Vavricka ST, Lichtenstein GR. Therap Adv Gastroenterol. 2021. [Epub ahead of print May 16 2021]. PMID: 34035832.

HTML

 

Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience & Recommendations.

Khanna D, Tande A, Rubin DT, Khoruts A, Kahn SA, Pardi D. Mayo Clin Proc. 2021;96(6):1418-1425. PMID: 34088413.

Achieving Histologic Normalization in Ulcerative Colitis is Associated with a Reduced Risk of Subsequent Dysplasia.

Shaffer SR, Erondu A, Traboulsi C, Rai V, Krugliak Cleveland N, Akiyama S, Christensen B, Rubin DT. Inflamm Bowel Dis. 2021. [Epub ahead of print May 25 2021].

Predictability of simple endoscopic score for Crohn’s disease (SES-CD) for postoperative outcomes in Crohn’s disease.

Akiyama S, Yamada A, Olleh JE, Komaki Y, Komaki F, Pekow J, Dalal SR, Cohen RD, Rubin DT, Sakuraba A. J Gastroenterol Hepatol. 2021. [Epub ahead of print May 11 2021]. PMID: 33973282.

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn’s disease.

Buisson A, Nancey S, Manlay L, Rubin DT, Hebuterne X, Pariente B, Fumery M, Laharie D, Roblin X, Bommelaer, Pereira B, Peyrin-Biroulet L, Vuitton L. United European Gastroenterol J. 2021;9(5):552-560. PMID: 33951350.

Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis.

Dwadasi S, Zafer M. Goens D, Paknikar R, Dalal S, Cohen RD, Pekow, Rubin DT, Sakuraba A, Micic D. Inflamm Bowel Dis. 2020. [Epub ahead of print December 15 2020.] PMID: 33319248.

The Correlation Between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn’s Disease.

Yamada A, Yuga K, Komaki F, Haider H, Micic D, Pekow J, Dalal D, Cohen RD, Cannon L, Umanskiy K, Smith R, Shogan BD, Hurst R, Hyman N, Rubin DT, Sakuraba A. Digestion. 2021. [Epub ahead of print February 8 2021]. PMID: 33556932.

International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

D’Amico F, Rubin DT, Kotze P, Magro F, Siegmund B, Kobayashi T, Olivera P, Bossuyt P, Pouillon L, Louis E, Domènech E, Ghosh S, Danese S, Peyrin-Biroulet L. United European Gastroenterol J. 2021. [Epub ahead of print May 7 2021]. PMID: 33961734.

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.

Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ< Sands BE, Walter R, Scholmerich J, Bemelman W, Danese S, Mary JY, Rubin DT, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A. Gastroenterology, 2021;160(5):1570-1583. PMID: 33359090.

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.

Siegel CA, Melmed GY, McGovern DPB, Rai V, Kramer DT, Rubin DT, Abreu MT, Dubinsky MC. Gut. 2021;70(4):635-640. PMID: 33472895.